Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
29.49
+0.15 (0.51%)
Sep 11, 2026, 11:44 AM EDT - Market open
Stoke Therapeutics Stock Forecast
Stock Price Forecast
According to 14 analysts polled by S&P Global, Stoke Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $46.46. The average 1-year stock price forecast is 57.54% higher than the current stock price, while the lowest is $35 (+18.68%) and the highest is $60 (+103.46%).
Price Target: $46.46 (+57.54%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Stoke Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 11 | 11 | 12 | 12 | 12 |
| Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 13 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| J.P. Morgan | J.P. Morgan | Buy Initiates $40 | Buy | Initiates | $40 | +35.64% | Aug 21, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $58 | Buy | Reiterates | $58 | +96.68% | Aug 13, 2026 |
| Wolfe Research | Wolfe Research | Buy Maintains $40 | Buy | Maintains | $40 | +35.64% | Aug 4, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $50 | Buy | Maintains | $50 | +69.55% | Aug 4, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Maintains $44 | Buy | Maintains | $44 | +49.20% | Aug 4, 2026 |
Financial Forecast
Revenue This Year
32.02M
from 184.42M
Decreased by -82.64%
Revenue Next Year
44.83M
from 32.02M
Increased by 39.98%
EPS This Year
-3.62
from -0.12
EPS Next Year
-3.52
from -3.62
EPS and Forward PE are based on non-GAAP adjusted numbers.